Skin cancer associated with the use of sorafenib and sunitinib for renal cell carcinoma.

@article{Breaker2013SkinCA,
  title={Skin cancer associated with the use of sorafenib and sunitinib for renal cell carcinoma.},
  author={Kathryn Breaker and Mary Naam and Francisco G. La Rosa and Insley P Flaig and Thomas Flaig},
  journal={Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]},
  year={2013},
  volume={39 7},
  pages={981-7}
}
BACKGROUND Several case series have reported an association between sorafenib and the development of skin cancer, but they differ in the reported rapidity of skin cancer onset and the frequency of recurrence with ongoing multikinase inhibitor (MKI) treatment. OBJECTIVE To compare the presentation and incidence of skin cancer in patients with renal cell carcinoma (RCC) treated with sorafenib and sunitinib. MATERIALS AND METHODS This retrospective study reviewed the records of 69 patients… CONTINUE READING